The surgical site infection control market shows promising growth prospects. Currently valued at USD 8.3 billion in 2025, this sector is expected to rise to USD 21.3 billion by 2035, at a compound annual growth rate (CAGR) of 9.9%. A significant factor supporting this market expansion includes the increasing volume of surgical procedures and escalating global awareness of healthcare-associated infections. These twin drivers are spurring demand for innovative infection prevention products and necessitating increased investment in hospital infection control programs and sterilization technologies worldwide.
Surgical drapes hold sway in the market landscape, with an 18.3% share, demonstrating the necessity for robust barrier protection in surgeries across numerous health centers and operating rooms globally. Health professionals continue to value the practicality advanced surgical drape products offer, such as high fluid resistance and antimicrobial barrier features, which are competitively priced and easily accessible via established medical supply networks.
Procedures such as cesarean sections emerge as vital application areas, representing a 16.9% share. Importance is placed on maternal safety and the necessity to prevent infections associated with obstetric surgical interventions. Other notable areas include superficial incisional surgical site infections (SSI), which demonstrate consistent growth driven by the increased focus on preventing wound contamination and optimizing surgical techniques.
Regionally, there is a myriad of opportunities, with North America maintaining strong market leadership through stringent regulatory standards and advanced hospital infection control programs. Simultaneously, the Asia Pacific region demonstrates rapid growth propelled by an increase in surgical volumes and modernizing healthcare infrastructure. India, in particular, leads growth with high surgical site infection rates and expanding surgical capacity.
To tap into this lucrative market, players including 3M, Getinge Group, Steris Healthcare, and BD, amongst others, utilize extensive product portfolios and advanced infection prevention mechanisms to establish a competitive edge. From 2025 to 2029, the surgical site infection control market is projected to grow from USD 8.3 to USD 11.8 billion, signaling a value increase of USD 3.5 billion, approximately 26.9% of the total forecast growth for the period.
This growth phase will be shaped by rising demand for antimicrobial surgical drapes and advanced skin preparation systems, innovations in antimicrobial-coated materials, and expanding integration with surgical safety protocols and infection surveillance systems.
The period from 2029 to 2035 is epitomized by the further expansion of specialized infection control applications, propelling the market from USD 11.8 billion to USD 21.3 billion. This growth will be accelerated by the strategic collaboration between hospital systems and infection control manufacturers and an amplified concentration on antimicrobial stewardship and evidence-based infection prevention standards.
Source: https://www.factmr.com/report/surgical-site-infection-control-market